Encore Capital Group approaches its May 6 Q1 results with an unusual setup: short sellers have been cutting positions even as the stock gave back some of its strong monthly gains, leaving the market in a state of quiet tension ahead of the print.
The most notable shift this week is in short positioning. Short interest has dropped 11% over the past week to around 5.1% of the free float — a meaningful retreat after a brief build-up in mid-April that pushed the figure closer to 6%. The lending market reflects that ease. Borrowing costs remain low at 0.48% annualised, well below where they sat in early April around 0.58%. Availability in the borrow pool is generous, with the 52-week utilisation peak of just 15.5% confirming this has never been a crowded short. There is no squeeze dynamic here — shorts are simply pulling back ahead of an event they appear unwilling to fight.
Options positioning tells a more nuanced story. The put/call ratio has dropped sharply to 3.82, running about 1.3 standard deviations below its 20-day average of 4.29, and down from a 52-week high of 5.66 reached in late March. In practical terms, the extreme put-heavy skew that characterised ECPG options through March and early April has moderated considerably. That is not outright bullishness — a ratio above 3 remains structurally put-heavy — but the direction of travel suggests hedging demand has cooled going into earnings. The ORTEX short score has also drifted lower this week to 44.4 from 47.6 ten days ago, consistent with the overall picture of easing short-side pressure.
The Street is broadly constructive, though recent analyst moves date to February rather than the current week. Following the Q4 2025 beat — which sent ECPG up 10% in a single session and 27% over five days — both Citizens and Truist raised their price targets meaningfully, to $90 and $80 respectively, while maintaining positive ratings. The consensus mean target now sits at $96.67, implying roughly 15% upside from the current $81.93 close. Valuation multiples remain undemanding: the P/E has crept up to 6.6x over the past month as the stock rallied 19%, yet EV/EBITDA has actually eased slightly to 8.4x. The EPS surprise factor score ranks in the 93rd percentile of the universe, and 90-day EPS momentum sits near the very top at the 98th percentile — two figures that help explain why analysts have been consistently nudging targets higher after each release. The RSI has climbed to 77, indicating the stock is technically extended after that 55% year-to-date run.
One institutional footnote worth noting: Vanguard filed two Schedule 13G filings on April 29, the same day the company released its annual report and proxy. The filings cover separate Vanguard entities and together represent ordinary passive-management reporting rather than a change in strategic intent. Turtle Creek, by contrast, cut its position by nearly 977,000 shares as reported at the last filing date — a significant trim from a focused active manager that held a 4.5% stake.
The Q4 result delivered a day-one move of 10% and a five-day follow-through of 27%. With the short-side stepping back, options hedging moderating, and the Street's targets sitting well above the current price, the May 6 print becomes a test of whether ECPG's collections-led earnings momentum can sustain the pace of estimate upgrades that has driven the stock's re-rating so far this year — and whether peers like PRAA, which gained 4.6% on the week versus ECPG's 1.8% loss, are drawing any of that rotation.
See the live data behind this article on ORTEX.
Open ECPG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
